world cancer report - iarc

Fig. 5.118 Five-year relative survival rates after
diagnosis of leukaemia.
REFERENCES
1. Freireich EJ, Lemak N (1991) Milestones in Leukemia
Research and Therapy, Baltimore, Maryland, Johns Hopkins
University Press.
2. IARC (2000) Ionizing Radiation, Part 1: X- and Gamma
Radiation and Neutrons (IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans, Vol. 75),
Lyon, IARCPress.
3. Noshchenko AG, Moysich KB, Bondar A, Zamostyan
PV, Drosdova VD, Michalek AM (2001) Patterns of acute
leukaemia occurrence among children in the Chernobyl
region. Int J Epidemiol, 30: 125-129.
4. IARC (2002) Non-ionizing Radiation, Part 1: Static and
Extremely Low-Frequency Electric and Magnetic
Fields (IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans, Vol. 80), Lyon, IARCPress.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds (2001)
World Health Organization Classification of Tumours.
Pathology and Genetics of Tumours of Haematopoietic and
Lymphoid Tissues, Lyon, IARCPress.
6. Farhi DC, Rosenthal NS (2000) Acute lymphoblastic
leukemia. Clin Lab Med, 20: 17-28, vii.
7. Estey EH (2001) Therapeutic options for acute myelogenous
leukemia. Cancer, 92: 1059-1073.
8. Alcalay M, Orleth A, Sebastiani C, Meani N,
Chiaradonna F, Casciari C, Sciurpi MT, Gelmetti V, Riganelli
ST-571, α-interferon and arabinosyl cytosine,
a chemotherapeutic agent, can produce
complete cytogenetic remissions, prevention
of blastic transformation and significant
prolongation of survival, with a small
fraction of patients being cured. However,
the development of resistance to ST-571
may cause patients to relapse within a few
months [14]. Without treatment, the life
span for the average individual with chronic
lymphocytic leukaemia is under five
years from diagnosis. The treatment for
this disease historically was with alkylating
agents. Recently the purine antimetabolite,
fludarabine, has substantially increased the
frequency and the quality of response to
chemotherapy. A new monoclonal antibody
directed against the T-cell antigen, CD52
D, Minucci S, Fagioli M, Pelicci PG (2001) Common themes
in the pathogenesis of acute myeloid leukemia. Oncogene,
20: 5680-5694.
9. Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999)
Chronic myelogenous leukemia: biology and therapy. Ann
Intern Med, 131: 207-219.
10. Keating MJ, O'Brien S (2000) Conventional management
of chronic lymphocytic leukemia. In: Foa R,
Hoffbrand, AV eds, Reviews in Clinical and Experimental
Haematology, 118-133.
11. Brenner MK, Pinkel D (1999) Cure of leukemia. Semin
Hematol, 36: 73-83.
12. Pui C-H, Campana D, Evans WE (2001) Childhood
acute lymphoblastic leukaemia - current status and future
perspectives. Lancet Oncology, 2: 597-607.
13. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ,
Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS,
Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment
with hyper-CVAD, a dose-intensive regimen, in adult
acute lymphocytic leukemia. J Clin Oncol, 18: 547-561.
14. McCormick F (2001) New-age drug meets resistance.
Nature, 412: 281-282.
(“CAMPATH”), has been found to be highly
effective in this disease. At the present
time, combinations of antimetabolite, alkylating
agents and monoclonal antibody in
various combinations and sequences are
being aggressively investigated and the
prognosis for patients in this category of
disease has substantially improved.
Generally, 60-70% of patients with acute
lymphoblastic leukaemia, and 20-30% of
patients with acute myeloid leukaemia (Fig.
5.118) survive in excess of five years.
Approximately 30-50% of the patients diagnosed
with chronic leukaemias survive five
years. Survival is much poorer in developing
countries (generally